RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) is the standard, evidence-based guideline used in oncology clinical trials to objectively assess how tumors respond to treatment. It classifies patient responses into four categories—Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD)—based on changes in tumor size.